VolitionRx Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

VolitionRx Limited, a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a ranage of cancers and other diseases, announced the pricing of its underwritten public offering of 3,809,524 shares of its common stock for gross proceeds of approximately $20 million.